Anterogen Co.

Seoul, South Korea

Anterogen Co.

Seoul, South Korea

Time filter

Source Type

News Article | February 28, 2017
Site: www.prnewswire.co.uk

According to a new market research report "Stem Cell Therapy Market by Type (Allogeneic, Autologous), Therapeutic Application (Musculoskeletal, Wound & Injury, CVD, Surgery, and aGVHD), Cell Source (Adipose tissue, Bone Marrow, Neural, Embryo/Cord Blood derived, iPSCs) - Global Forecasts to 2021" published by MarketsandMarkets, the market is expected to reach USD 145.8 Million by 2021, growing at a CAGR of 11.0%. Browse 60 market data Tables and 37 Figures spread through 120 Pages and in-depth TOC on "Stem Cell Therapy Market" Early buyers will receive 10% customization on this report. The report analyzes and studies the major market drivers, restraints, opportunities, and challenges in North America, Europe, Asia-Pacific, and the Rest of the world (RoW) for the forecast period of 2016 to 2021. Factors such as the growing awareness related to the therapeutic potency of stem cells in disease management, development of advanced genome-based cell analysis techniques, increasing public-private investments for stem cell research, identification of new stem cell lines, and developments in infrastructure for stem cell banking and processing are propelling the growth of the global Stem Cell Therapy Market. On the basis of type, the global Stem Cell Therapy Market is divided into two major categories, namely, allogeneic stem cell therapy and autologous stem cell therapy. The allogeneic stem cell therapy segment is expected to command the largest share in the global Stem Cell Therapy Market in 2016. This large share can primarily be attributed to the rising commercialization of allogeneic stem cell therapy products, wider therapeutic applications of allogeneic stem cells, easy production scale-up process, and growing number of clinical trials related to allogeneic stem cell therapies. On the basis of therapeutic application, the global Stem Cell Therapy Market is segmented into musculoskeletal disorders, wounds and injuries, cardiovascular diseases, surgeries, gastrointestinal diseases, and other applications. The musculoskeletal disorders segment is expected to command the largest share of the global Stem Cell Therapy Market in 2016. This large share can be attributed to the rising availability of stem cell-based products for the treatment of musculoskeletal disorders, high prevalence of musculoskeletal disorders and bone & joint diseases, and growing patient preference for effective & early treatment strategies. North America is expected to be the largest regional segment in the global Stem Cell Therapy Market in 2016, followed by Asia-Pacific. In addition, the North American Stem Cell Therapy Market is expected to be the fastest growing region during the forecast period. Factors such as growing awareness related to the therapeutic potency of stem cells, increasing number of clinical trials for stem cell-based products, and increasing public-private funding & research grants are driving the growth of this market. As of 2015, Osiris Therapeutics, Inc. (U.S.), MEDIPOST Co., Ltd. (South Korea), Anterogen Co., Ltd. (South Korea), Pharmicell Co., Ltd. (South Korea), Holostem Terapie Avanzate S.r.l. (Italy), JCR Pharmaceuticals Co., Ltd. (Japan), NuVasive, Inc. (U.S.), RTI Surgical, Inc. (U.S.), and AlloSource (U.S.) are some of the key players operating in the global Stem Cell Therapy Market. Stem Cell Banking Market by Bank Type (Cord Blood, and Cord Tissue), Service (Collection & Transportation, Analysis, Processing, and Storage), Application (Cerebral Palsy, Leukemia, Thalassemia, Anemia, Autism, Diabetes), Region - Forecast to 2021 MarketsandMarkets is the largest market research firm worldwide in terms of annually published premium market research reports. Serving 1700 global fortune enterprises with more than 1200 premium studies in a year, M&M is catering to a multitude of clients across 8 different industrial verticals. We specialize in consulting assignments and business research across high growth markets, cutting edge technologies and newer applications. Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. M&M's flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. The new included chapters on Methodology and Benchmarking presented with high quality analytical infographics in our reports gives complete visibility of how the numbers have been arrived and defend the accuracy of the numbers. We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository. Connect with us on LinkedIn @ http://www.linkedin.com/company/marketsandmarkets


The present invention relates to a stable and readily usable administration type including a composition including mesenchymal stem cells cultured in hydrogel, more specifically, a adipose tissue-derived mesenchymal stem cell-hydrogel composition and a method of preparing the same. More specifically, the present invention relates to a composition including mesenchymal stem cells cultured in hydrogel, washed, and filled into a syringe, wherein the composition of the present invention may be readily administered without modification and may not need an enzyme treatment in a final process of preparing transplanted cells, almost no cell is lost because the composition is washed as hydrogel without an washing process using centrifugation or other methods, and the therapeutic effect is shown immediately after administration to an individual because bioactive substances are patched in pores of the hydrogel.


Patent
Anterogen Co. | Date: 2014-09-29

Provided is a composition for preventing or treating IL-17-related diseases, more specifically, autoimmune diseases and inflammatory diseases induced by an increase of IL-17. The IL-17 production inhibitory composition is characterized by containing mesenchymal stem cells originated from an adipose tissue as an active ingredient. This IL-17 production inhibitory composition is efficacious in preventing or treating diseases caused by the IL-17 production. The said diseases are selected from the group consisting of Kawasaki disease, microscopic polyangitis, adult-onset Stills disease, Stevens-Johnson syndrome and toxic epidermal necrolysis.


The present invention relates to a composition comprising mesenchymal stem cell-hydrogel-biodegradable support or mesenchymal stem cell-hydrogel-undegradable support, a sheet comprising the composition and a method for the preparation thereof. By using the sheet comprising the adipose-derived mesenchymal stem cell-hydrogel biodegradable or undegradable support, stem cells of high activity may be applied directly to the wound without isolation process using protease. The sheet has extracellular matrices such as collagen, laminin, fibronectin and elastin secreted by stem cells in the culture stage and included completely in the hydrogel, and therefore it has superior skin regeneration and wound healing effects compared with conventional pharmaceutical preparations and shortens therapeutic period.


The present invention relates to a method for producing clinically effective quantities of human adipose tissue-derived stromal cells for treating fistulas and a composition made with the same. The method of the present invention can efficiently produce clinically effective number of adipose tissue-derived stromal cells within a short period by improving conventional standard culturing methods. The adipose stem cells composition containing the adipose tissue-derived stromal cells obtained by the method of the present invention exhibit superior multipotency and immunomodulatory activity over those of a cell composition produced by conventional methods, and thus is more suitable for treating fistulas. The cell composition of the present invention has excellent clinical usages especially since immune response is suppressed in allogenic adipose-derived stem cells.


Patent
ANTEROGEN Co., Korea Research Institute of Bioscience and Biotechnology | Date: 2014-06-11

The present invention relates to: a composition for detecting a marker for detecting the proliferation capacity or treatment capacity of adipose-derived stem cells cultured in a medium containing epidermal growth factor (EGF) or basic fibroblast growth factor (bFGF); and a detection method.


Patent
Korea Research Institute of Bioscience, Biotechnology and Anterogen Co. | Date: 2016-04-20

The present invention relates to: a composition for detecting a marker for detecting the proliferation capacity or treatment capacity of adipose-derived stem cells cultured in a medium containing epidermal growth factor (EGF) or basic fibroblast growth factor (bFGF); and a detection method.


Patent
Anterogen Co. | Date: 2016-08-10

Provided is a composition for preventing or treating IL-17-related diseases, more specifically, autoimmune diseases and inflammatory diseases induced by an increase of IL-17. The IL-.17 production inhibitory composition is characterized by containing mesenchymal stem cells originated from an adipose tissue as an active ingredient. This IL-17 production inhibitory composition is efficacious in preventing or treating diseases caused by the IL-17 production. The said diseases are selected from the group consisting of Kawasaki disease, microscopic polyangitis, adult-onset Stills disease, Stevens-Johnson syndrome and toxic epidermal necrolysis.


The present invention relates to a composition comprising mesenchymal stem cell-hydrogel-biodegradable support or mesenchymal stem cell-hydrogel-undegradable support, a sheet comprising the composition and a method for the preparation thereof. By using the sheet comprising the adipose-derived mesenchymal stem cell-hydrogel biodegradable or undegradable support, stem cells of high activity may be applied directly to the wound without isolation process using protease. The sheet has extracellular matrices such as collagen, laminin, fibronectin and elastin secreted by stem cells in the culture stage and included completely in the hydrogel, and therefore it has superior skin regeneration and wound healing effects compared with conventional pharmaceutical preparations and shortens therapeutic period.


The present invention relates to a method for producing clinically effective quantities of human adipose tissue-derived stromal cells for treating fistulas and a composition made with the same. The method of the present invention can efficiently produce clinically effective number of adipose tissue-derived stromal cells within a short period by improving conventional standard culturing methods. The adipose stem cells composition containing the adipose tissue-derived stromal cells obtained by the method of the present invention exhibit superior multipotency and immunomodulatory activity over those of a cell composition produced by conventional methods, and thus is more suitable for treating fistulas. The cell composition of the present invention has excellent clinical usages especially since immune response is suppressed in allogenic adipose-derived stem cells.

Loading Anterogen Co. collaborators
Loading Anterogen Co. collaborators